AstraZeneca plc stock price

A number of companies and research teams around the globe are struggling to develop a vaccine against the SARS-CoV-2 virus, which causes Covid-19. Billions and billions of dollars have been spent to develop a vaccine in the shortest possible time frame Certain media reports note that six coronavirus vaccines are the final stage of human trials – three from China, one from the UK (AZN/Oxford), and two from the U.S. (Pfizer/BioNTech and Moder...

AstraZeneca plc (LON: AZN) said on Monday that it is set to resume its late-stage clinical trial of the experimental COVID-19 vaccine. The optimism was well received as the pharmaceutical company’s stock rallied to deliver the strongest boost to the FTSE 100 on Monday. Shares of the company opened about 1% up on Monday but lost the entire gain in the next hour as President Donald Trump ordered drug companies to reduce prices in the United States...

In an announcement on late Tuesday, AstraZeneca plc (LON: AZN) said that late-stage trial for its candidate COVID-19 vaccine had been paused after a study participant met with an unexplained severe adverse reaction. AstraZeneca’s experimental vaccine was among the top candidates of a potential cure for the novel flu-like virus. Spokeswoman Michele Meixell of AstraZeneca commented in an emailed statement on Tuesday: “Our standard review process wa...

AstraZeneca plc (LON: AZN) announced to have started the late-stage trial of its experimental COVID-19 vaccine in the United States that it is calling AZD 1222 on Tuesday. The company said its late-stage testing that is funded by the U.S. government (Operation Warp Speed) will see participation from 30,000 subjects.   AstraZeneca opened more than 1% up in the stock market on Tuesday but tanked roughly 2% in the next few hours. At a per-share...

Shares of AstraZeneca PLC (LON: AZN) gained over 1% on reports that the U.S. government considers fast-tracking the approval for Astrazeneca’s coronavirus vaccine in the States before the forthcoming presidential elections, according to a report by the Financial Times.  Fundamental analysis: Unrealistic scenario? The FT report said that President Donald Trump is considering several options, one of them including the FDA’s approval for the emergen...

AstraZeneca plc (LON: AZN) said on Thursday that its net profit in the second quarter came in stronger on a year over year basis. The company also highlighted that its candidate vaccine for the treatment of COVID-19 is now in late-stage trials. In June, AstraZeneca announced to have secured £18.60 million of funding from the United States Biomedical Advanced Research and Development Authority (BARDA). Shares of the company opened just under 1% up...

In an announcement on Tuesday, AstraZeneca (LON: AZN) revealed that the U.S. Biomedical Advanced Research and Development Authority (BARDA) funded £18.60 million to help the drug manufacturer ramp up production of its experimental COVID-19 vaccine. Oxford Biomedical also recently partnered with VMIC to speed up the production of AstraZeneca’s vaccine. Shares of the company are currently 1% up on Wednesday. At £83.21 per share, the most valuable L...

AstraZeneca (LON: AZN) is committed to delivering a minimum of 2 billion doses of its experimental COVID-19 vaccine in 2020 and 2021. In an announcement on Monday, Oxford Biomedica (LON: OXB) said that it had partnered with a British government-backed group to ramp up production of AstraZeneca’s candidate vaccine. The partnership, the cell therapy company added, is aimed at satisfying the rising global demand for the Coronavirus vaccine, includin...

AstraZeneca (LON: AZN) is collaborating with the University of Oxford to develop its COVID-19 vaccine.  In a statement on Thursday, the company said that results of its clinical trial (early stage) are expected presently. Upon successful testing, the drug manufacturer said, it will commit to supplying at least 1 billion doses in 2020 and 2021. The announcement also highlighted the British pharmaceutical company to have signed the 1st agreeme...

British pharmaceutical company, AstraZeneca (LON: AZN) collaborated with the U.S-based Merck & Co. (NYSE: MRK) on Lynparza drug as a treatment option for prostate cancer. On Wednesday, the two companies gave a joint statement that Lynparza received approval from the United States Food and Drug Administration (FDA). According to the FDA, Lynparza is now authorised to be used to treat a form of prostate cancer that is known to not respond to th...

AstraZeneca (LON: AZN) is testing Farxiga as a potential cure for organ failure and other dire complications in Coronavirus patients with an existing kidney or heart condition. In its announcement on Thursday, the biopharmaceutical company said that its diabetes drug is now in late-stage testing. The trial is the drug manufacturer’s 2nd attempt at investigating the potential of an existing therapy as a treatment option for COVID-19 patients...

AstraZeneca is the latest in the list of firms that anticipated a major hit to the performance ascribed to the recent outbreak of Coronavirus in China. While the outlook for the next quarters wasn’t too optimistic, the pharmaceutical company highlighted that its operations have so far not been disrupted significantly due to the health emergency. AstraZeneca has a reputation for one of the largest drug makers across the globe. Following Frid...

On Monday, AstraZeneca, a biopharmaceutical company devoted to research and development of innovative drugs, revealed that it will soon discontinue Epanova, a heart disease drug to be used by people suffering from mixed dyslipidemia. The testing for the drug will be halted in its late-stage trial resulting in a drop of around $100 million in profits for the fourth quarter.Following recommendations made by an independent company monitoring the pro...

In the recent news, the FTSE 100 index has been observed trading higher than expected this morning, Thursday, October 24th, 2019. While the Brexit uncertainty was expected to keep the financial markets under pressure until the decision from the European Union regarding UK’s request for an extension wasn’t announced, the market opened at 7,260 level and presented an immediate hike to 7,320.66 within an hour. The index is currently trad...

The FTSE 100 has started the week on the back foot, pressured by a fall in miners and financials, amid uncertainty over the trade talks between the US and China. Blue-chip travel shares meanwhile have been in demand as tour operator Thomas Cook Group (LON:TCG) collapsed. FTSE 100 loses ground As of 12:15 BST, the Footsie had given up 36.24 points to stand 0.49 percent lower at 7,308.68. Market sentiment has been subdued this Monday after Chinese...

AstraZeneca’s (LON:AZN) share price has advanced in London this Monday as one of its diabetes treatments was recommended for marketing authorisation in the European Union. The news marks a boost for the Anglo-Swedish drugmaker which has bet on new medicines in several therapy areas to propel growth going forward. As of 11:05 BST, AstraZeneca’s share price had added 0.53 percent to 7,205.00p, outperforming the broader UK market, with t...

AstraZeneca (LON:AZN) has moved to amend a deal with Ironwood to take control of Linzess in China, the Anglo-Swedish drugmaker has said. The move comes after the two companies first entered into a collaboration to co-develop and co-commercialise the treatment in 2012. AstraZeneca’s share price has climbed higher in London this morning, having gained 0.46 percent to 6,923.00p as of 10:04 BST. The stock is outperforming the broader UK market,...

AstraZeneca’s (LON:AZN) share price has climbed higher in London in today’s session this Wednesday as analysts at Citi reiterated their ‘buy’ rating on the stock and lifted their valuation. Sharecast quoted the broker as commenting that the market continued to  under-appreciate the commercial potential and operating leverage from the pharmco’s treatments such as Tagrisso, Lynparza, roxadustat and Farxiga. As of...

the Anglo-Swedish drugmaker posted upbeat late-stage trial results for its oncology treatment Imfinzi. The results mark a boost for the company which has chosen oncology as one of its key therapy areas to propel growth as the drugmaker battles with declining sales of older blockbuster treatments. As of 08:53 BST, AstraZeneca’s share price had climbed 0.45 percent to 7,288.00p, outperforming the broader UK market, with the benchmark FTSE 100 index...

JPMorgan remains ‘overweight’ on AstraZeneca, pointing to positive trends for the FTSE 100 company and peers Novo and Roche seen in the first half of the year, and positive outlook going forward, Sharecast reports. The update comes follows a string of positive news for some of the Anglo-Swedish drugmaker’s treatments this week. AstraZeneca’s share price has advanced in London in today’s session, having gained 0.64 pe...